MTEM vs. BOLT, SABS, WVE, COGT, MRUS, BMY, AMGN, VRTX, REGN, and GILD
Should you be buying Molecular Templates stock or one of its competitors? The main competitors of Molecular Templates include Bolt Biotherapeutics (BOLT), SAB Biotherapeutics (SABS), Wave Life Sciences (WVE), Cogent Biosciences (COGT), Merus (MRUS), Bristol-Myers Squibb (BMY), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD). These companies are all part of the "medical" sector.
Bolt Biotherapeutics (NASDAQ:BOLT) and Molecular Templates (NASDAQ:MTEM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, community ranking, valuation, earnings and institutional ownership.
Bolt Biotherapeutics has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Molecular Templates has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500.
In the previous week, Bolt Biotherapeutics and Bolt Biotherapeutics both had 2 articles in the media. Bolt Biotherapeutics' average media sentiment score of 0.73 beat Molecular Templates' score of 0.38 indicating that Molecular Templates is being referred to more favorably in the news media.
86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 95.5% of Molecular Templates shares are held by institutional investors. 30.9% of Bolt Biotherapeutics shares are held by company insiders. Comparatively, 18.7% of Molecular Templates shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Bolt Biotherapeutics currently has a consensus target price of $3.50, indicating a potential upside of 362.53%. Given Molecular Templates' higher probable upside, equities analysts plainly believe Bolt Biotherapeutics is more favorable than Molecular Templates.
Molecular Templates received 262 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. Likewise, 67.32% of users gave Molecular Templates an outperform vote while only 65.57% of users gave Bolt Biotherapeutics an outperform vote.
Molecular Templates has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Molecular Templates, indicating that it is currently the more affordable of the two stocks.
Molecular Templates has a net margin of -57.92% compared to Molecular Templates' net margin of -556.59%. Molecular Templates' return on equity of -51.74% beat Bolt Biotherapeutics' return on equity.
Summary
Molecular Templates beats Bolt Biotherapeutics on 9 of the 15 factors compared between the two stocks.
Get Molecular Templates News Delivered to You Automatically
Sign up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MTEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Molecular Templates Competitors List
Related Companies and Tools
